GL1X · GenesisL1 explorer

Research workbench

PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5- YL)METHYL]-5-methyl-pyrimidin-4-amine

Analyse PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5C2A
Type
protein
Length
646 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Camp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10A
EC
3.1.4.17, 3.1.4.35
UniProt
Q9Y233
Ligands
4Y2, ZN, MG
Pockets
5 · best druggability 0.81

Structure

x-ray diffraction · 1 distinct chain · 72% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BCamp and camp-inhibited cgmp 3',5'-cyclic phosphodiesterase 10A (EC 3.1.4.17, 3.1.4.35)protein32372% helix, 0% strandQ9Y233

Ligands and binding sites

  • 4Y2 · 6-chloro-2-cyclopropyl-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-methylpyrimidin-4-amine · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17750.810.8480MG, 4Y2
23970.710.8243MG, 4Y2
3950.410.7721empty
41050.390.7522empty
5560.290.7514empty

Interfaces

1 interface between chains.

  • A–B · 465 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 5C2A · PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.